Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.
Type:
Grant
Filed:
February 18, 2021
Date of Patent:
May 7, 2024
Assignee:
VTV THERAPEUTICS LLC
Inventors:
Jennifer L. R. Freeman, Maria Carmen Valcarce Lopez
Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.
Abstract: The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.
Type:
Grant
Filed:
June 7, 2021
Date of Patent:
April 23, 2024
Assignee:
President and Fellows of Harvard College
Inventors:
Lee L. Rubin, Amy J. Wagers, Amanda K. W. Gee, Feodor D. Price
Abstract: Disclosed herein is a composition comprising a biologically active agent; a base oil; an additional oil that is soluble in the base oil with a partition coefficient for the biologically active molecule that is at least twice that of the base oil; where the base oil and the additional oil are present in the composition in an amount effective to reduce the amount of the biologically active agent in an aqueous phase to less than 80 wt % of the amount with just the base oil present in an otherwise identical composition at the same total oil loading; a non-ionic surfactant; and water.
Type:
Grant
Filed:
November 30, 2021
Date of Patent:
April 23, 2024
Assignee:
University of Florida Research Foundation, Inc.
Abstract: Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
April 16, 2024
Assignee:
Trustees of Tufts College
Inventors:
William W. Bachovchin, Hung-sen Lai, Wengen Wu
Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.
Abstract: The present invention relates to methods of treating certain retinal vasculopathies such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration, among others. The method includes treating a patient suffering from a retinal vasculopathy by administering to the patient a therapeutically effective dose of a compound as disclosed herein.
Abstract: The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed.
Abstract: Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
Type:
Grant
Filed:
July 15, 2021
Date of Patent:
April 9, 2024
Assignee:
Novartis AG
Inventors:
Irina Baltcheva, Peter End, Julie Marie-Pomme Gabrielle Milojevic
Abstract: In an embodiment, the invention is directed to prodrug compounds of L-BHDU according to the chemical structure I: Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group; R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group; R1a is independently a C6-C30 alkyl group, often a C12-C22 alkyl group, often a C14-C20 alkyl group or a C16-C18 alkyl group, often a C16 or C18 alkyl group; R2a is independently a C1-C12 alkyl group, often a C2-C6 alkyl group, a C3-C4 alkyl group, an isopropyl, t-butyl or sec-butyl group, or an isopropyl or t-butyl group; Each j is independently 1-6, 1-3, often 1 or 2; Each k is 0 or 1; Each n is independently 1-6, 1-4, 2-4 or 2 or 3; or A pharmaceutically acceptable salt, solute or polymorph thereof. Additional embodiments are directed to pharmaceutical compositions based upon the disclosed chemical compounds and methods of treating or reducing the likelihood of VZV, HSV-1 or HSV-2 infections.
Type:
Grant
Filed:
October 28, 2022
Date of Patent:
April 2, 2024
Assignees:
University of Georgia Research Foundation, Inc., Anterogen Co., Ltd.
Abstract: Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, Alzheimer's disease, Parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided. The compositions may be topically applied to skin or mucous membranes.
Type:
Grant
Filed:
May 19, 2021
Date of Patent:
March 19, 2024
Assignee:
Concordia University
Inventors:
Abhay Singh Chauhan, Eric Andrew Newenhouse, Armin Henry Gerhardt
Abstract: Disclosed are pharmaceutical compositions and oral dosage forms including capsules containing (17-?)-3-oxoandrost-4-en-17-yl tridecanoate, and related methods. The capsule fill can include an additive and about 14 wt % to about 42 wt % for androst-4-en-17?-ol-3-one esters that comprise (17-?)-3-oxoandrost-4-en-17-yl tridecanoate or a combination of (17-?)-3-oxoandrost-4-en-17-yl undecanoate, (17-?)-3-oxoandrost-4-en-dodecanoate, and (17-?)-3-oxoandrost-4-en-17-yl tridecanoate. A single oral administration to a male subject of one or more dosage forms with a total androst-4-en-17?-ol-3-one equivalent dose of about 150 mg to about 895 mg is provided. In another embodiment, a method for providing a serum concentration of androst-4-en-17?-ol-3-one within a target PK performance for a male subject is provided.
Type:
Grant
Filed:
September 30, 2021
Date of Patent:
March 19, 2024
Inventors:
Kilyoung Kim, Mahesh V. Patel, Nachiappan Chidambaram
Abstract: The present invention relates to a new use of compounds that are angiotensin II (Ang II) agonists, more particularly agonists of the Ang II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to the AT2 receptor, for the prevention or treatment of muscular dystrophy or complications associated with muscular dystrophy.
Abstract: Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
Abstract: A pharmaceutical composition is suitable for treating AXL-related cancer. The cancer can be cancer with high expression of AXL. The cancer can also be cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent. Specific diamino heterocyclic carboxamide compounds have an AXL inhibitory action, and pharmaceutical compositions comprising these compounds as an active ingredient have a therapeutic effect on AXL-related cancer. This AXL-related cancer can be cancer with high expression of AXL and/or cancer which has acquired resistance by the activation of AXL against therapy with an anticancer agent.
Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.
Type:
Grant
Filed:
March 16, 2022
Date of Patent:
March 12, 2024
Assignee:
SPECNOVA LLC
Inventors:
Sebastian Balcombe, William Hamilton, Jonathan Heal, Joseph Sheridan
Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.